EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Chitosan-coated silver nanoparticles amplify glycopeptide efficacy against Staphylococcus aureus

Sakshi V Khairnar, Anna Sommers, Elena Muldiiarova, Kenneth W Bayles, David Oupický, Vinai C Thomas, Marat R Sadykov, Svetlana Romanova

Frontiers in Microbiology · 24.06.2026 · 17

DOI: 10.3389/fmicb.2026.1787175 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Microbiology, online erschienen am 24.06.2026. Verfasst von Sakshi V Khairnar und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, United States. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The escalating prevalence of antibiotic resistance represents a critical threat to global public health, while the development of new antibiotics remains limited. Vancomycin, a glycopeptide antibiotic, is essential for treating severe Gram-positive infections. However, the emergence of vancomycin-intermediate (VISA) and vancomycin-resistant (VRSA) Staphylococcus aureus strains has raised significant concerns due to their challenging resistance profiles and limited treatment options. In this study, we developed a carboxylic acid-capped silver nanoparticle (AgNPs) platform to enhance the therapeutic delivery and efficacy of vancomycin. The nanocomposite (AgNPs/Van/CS) was engineered by leveraging electrostatic interactions between AgNPs and vancomycin, with a chitosan coating to provide stability, bacterial adhesion, and improved biocompatibility. Our results demonstrate that AgNPs/Van/CS significantly outperformed vancomycin alone, exhibiting enhanced antibacterial and antibiofilm activity against both methicillin-sensitive (MSSA) and methicillin-resistant (MRSA) S. aureus strains, as well as vancomycin-intermediate (VISA) clinical isolates. Notably, AgNPs/Van/CS achieved potent bacterial inhibition at lower antibiotic concentrations and significantly reduced biofilm formation, while maintaining strong activity under diverse laboratory conditions. These findings highlight the potential of AgNPs/Van/CS as a promising strategy for managing S. aureus infections and addressing the urgent challenge of antibiotic resistance.

Schlagwörter

Stichwörter der Autor:innen

Staphylococcus aureusantibiotic resistanceantimicrobial agentsglycopeptide antibioticssilver nanoparticlesvancomycin

Autor:innen und Institutionen

  • Center for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, United States.
  • Department of Pathology, Microbiology and Immunology, University of Nebraska Medical Center, Omaha, NE, United States.

Zitieren

APA

Khairnar, S. V., Sommers, A., Muldiiarova, E., Bayles, K. W., Oupický, D., Thomas, V. C., Sadykov, M. R., & Romanova, S. (2026). Chitosan-coated silver nanoparticles amplify glycopeptide efficacy against Staphylococcus aureus. Frontiers in Microbiology, 17. https://doi.org/10.3389/fmicb.2026.1787175

Vancouver

Khairnar SV, Sommers A, Muldiiarova E, Bayles KW, Oupický D, Thomas VC, et al. Chitosan-coated silver nanoparticles amplify glycopeptide efficacy against Staphylococcus aureus. Frontiers in Microbiology. 2026;17. doi:10.3389/fmicb.2026.1787175

BibTeX
@article{Khairnar2026,
  author = {Khairnar, Sakshi V and Sommers, Anna and Muldiiarova, Elena and Bayles, Kenneth W and Oupický, David and Thomas, Vinai C and Sadykov, Marat R and Romanova, Svetlana},
  title = {Chitosan-coated silver nanoparticles amplify glycopeptide efficacy against Staphylococcus aureus},
  journal = {Frontiers in Microbiology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fmicb.2026.1787175}
}
Kostenlos starten →